Parkinson's disease (PD) can be caused by genetic changes in a lot of genes. The effect of these changes is determined by the nature of the mutation and ranges from weak associations to pathogenic mutation which leads to loss of protein function. Our study is based on epidemiological data which show significantly increased prevalence of PD (2.9 %) in an isolated population of
INTRODUCTION
Parkinson's disease, the second most common neurodegenerative disorder affecting 1% of the population over 65 years, was described in 1817 by James Parkinson [1, 2] . The disease is characterized by a selective loss of dopamine in the substantia nigra pars compacta which leads to abnormal motor symptoms such as resting tremor, stiffness (rigidity), general slowness of movement (bradykinesia) and decreasing of facial expression [3, 4] . The cause of PD is not known, but several neurotoxins have been shown to cause parkinson's-like neuropathology in animals [5] . Further, several genes associated with autosomal dominant and autosomal recessive PD have been described (SNCA, UCHL1, LRRK2, GIGYF2, OMI/HTRA2, PARK2, PINK1, PARK7, ATP13A2) [6] . The segregation analyses which were published by independent studies confirmed the influence of genetic background on the age of PD onset. In general, stronger major effect genes have been described for penetrance or the age of onset than for disease susceptibility [7, 8] . It has been described that prevalence in small isolated families is higher in Europe [9, 10] . A higher prevalence of Parkinsonism has been recently identified in the South-Eastern Moravia (Czech Republic). Particularly, aggregation of Parkinsonism was found in two large family trees. This is probably caused by the isolation of the regional population due to the very low migration rate of its inhabitants to neighbouring regions in the last two centuries [11] .
The aim of the study is:
to compare two different Next Generation
Sequencing (NGS) data analysis approaches in PD patients in the genes responsible for Parkinsonism.
2. to describe the most important findings in the patients with comparison to controls.
METHODS
A set of twenty eight patients with Parkinson's disease and 12 healthy controls were analyzed. practitioners (GP). During three-months, questionnaires were filled in by patients who visited GP for any reason. Further, respondents screened as positive for parkinsonism (after their signing the informed consent with further examination) were investigated by primary care neurologists. The motor part of the Unified Parkinson's Disease Rating Scale (UPDRS) was completed. Subsequently a preliminary parkinsonism's diagnosis was made and or rejected. Finally, individuals with parkinsonism were examined in a tertiary movement disorders centre in University Hospital Olomouc. There they were examined by a neurologist with detailed movement disorders expertise [12] . Average age of patients was 67 years (from 45 to 90 years) and controls from the same region were older than 70 or, in case of known pedigree, 5 year older than individual with the disease symptoms. Study was approved by Ethical Committee of University Hospital Olomouc, Czech Republic. The patients were informed in detail about the study and signed informed consent. DNA was isolated from peripheral blood by isolation kit (QIAamp DNA Mini Kit-Qiagene). DNA concentration was measured fluorometrically (Qubite -Qiagene). Each DNA sample was diluted in water to a final concentration 10 ng/µL. Amplicon library was in silico designed by Ion AmpliSeq Designer (Thermo Fisher Scientific) for ADH1C, EIF4G1, FBXO7, GBA + GBAP1, GIGYF2, HTRA2, LRRK2, MAPT, PARK2, PARK7, PINK1, PLA2G6, SNCA, UCHL1 and VPS35 genes. In total 617 amplicons covered 92.59% of CDS including 100bp into the introns and both 3' and 5' UTRs of the regions. Coverage of amplicon control: Amplicons were checked in Torrent Suite using plugin Coverage Analysis. 1000 Genomes Project (1000G) and Exome Aggregation (ExAC) population allele frequency databases were used for MAF filtering and for assessment of allele frequency differences [13, 14] .
Data analysis and variant searching (Mapping, Variant calling, Annotation) were done using: 1) Torrent Suite and Ion Reporter: Data from PGM were collected and converted to Fastq and BAM formats using Ion Torrent Suite software. The "Bam/Bai" and "vcf" files were reloaded to Ion Reporter v4.6 and variant calling workflow was in the first level relaxed to minimal amplicon coverage 4 and minimal ratio of alternative/common variant 0.1.
Variants were then filtered using following parameters: AQ>20; Read coverage>20; MAF from 1000G and/or from ExAC<1%; for missense polymorphisms SIFT: 0-0.05 and/or PolyPhen-2: 0.2-1. MAF was relaxed to 5% if both the SIFT and PolyPhen predictors indicate gene impairment.
2) Torrent Suite and NextGENe (Softgenetics):
Data obtained from PGM were saved in Fastq, then using NextGENe software data were converted to Fasta format, adapted for Ion Torrent platform and mapped to the specific reference sequences. Variant was assessed using GRCh37 dbSNP135 and ClinVar reference genome databases.
Variants were then filtered as mentioned above in 1). All filtered in variants were then verified and confirmed by Sanger sequencing. SIFT and PolyPhen-2 prediction softwares were used for missense variants evaluation. PhyloP algorithm was used to assess the phylogenetical conservation.
To assess population frequency differences between patients and control and between patients and 1000G and/or ExAC data we used Pearson's chi-squared test.
RESULTS
Basic sequencing coverage statistics are displayed in Table 1 . Almost 100% of targets were sequenced with coverage 1x-19x and circa 97% with coverage 20x-100x.
Percentage of completely sequenced amplicon (end-to-end) was lower (from 38.5% -to 80%).
Variant calling statistics
Before filtering out (mostly population common variants) we found an average of 70 and 72 variants per sample (maximum 101 and 100/minimum 48 and 55) using Ion Reporter and NextGENe, respectively.
After filtering out, three missense mutations were found using Ion Reporter and NextGENe in LRRK2 gene:
rs33995883 (p.Asn2081Asp), rs33958906 (p.Pro1542Ser), rs781737269 (p.Ser633Phe), one missense mutation in MAPT gene rs63750072 (p.Gln230Arg) and one mutation in HTRA2 gene rs72470545 (p.Gly399Ser). Table 2 describes particular mutations and summarises allelic frequency in patients and control and also frequency from 1000G and ExAC databases.
Rare missense variant calling from the NextGENe with Ion Torrent adaptation and Torrent Suite/ Ion Reporter had a 100% correlation.
DISCUSSION
We used two variant calling approaches in order to compare both methods and in order to assess the ability of each method to capture particular rare variant. Another reason is to ensure that we, if possible, do not miss any rare variant.
Most variants were common and in non-coding regions. We did not observe any previously described causal mutation or variant which could be considered as founder mutation in our group of patients. So we suppose that an accumulation of several rare variants could together lead to increasing susceptibility to the disease.
Missense LRRK2 mutations belong to the most common cause of familial forms of Parkinsonism [15] [16] [17] .
While common variant can increase the risk of sporadic form of Parkinsonism [18, 19] , mutation p.Gly2019Ser occurs in both familial and sporadic forms [20, 21] . The substitutions p.Arg1441Cys and p.Tyr1699Cys are associated with loss of neurons [17, 22] . Furthermore, mutations p.Asn1437His, p.Ile2020Thr and p.Arg1441Gly were found to be associated with the disease [23, 24] .
The missense variant described in our study (rs33995883; p.Asn2081Asp) was identified in 6/0 patient/control (p/c) and it is located in phylogenetically conserved region (phyloP score 7.2). Prediction tools evaluated it as benign (SIFT score 0.081) and as pathogenic (PolyPhen-2 score 0.983). The exchange uncharged polar for acidic amino acid supported pathogenic role. On the other hand, the study from Benitez et al. 2016 found the allelic frequency 1.8% in patients and 2.2% controls, which supports it's benign role [25] . Also, the variant was described by the study Foo et al., 2014 in none of patient and in 0.25% of the controls [26] .
So, it could be concluded that the variant can be either population specific in association with Parkinsonism or has no influence on PD.
The second LRRK2 variant found was rs33958906; p.Pro1542Ser. The variant is located in the COR domain LRRK2 [27] score 5.3) and it was identified in 1/1 p/c. It leads to exchange nonpolar for uncharged polar amino acid, so it could be pathogenic character which is supported by PolyPhen-2 prediction (probably damaging, PolyPhen-2 score 0.962) and predicted benign by SIFT (SIFT score 0.159). Di Fonzo et al. (2006) found allele T in 1.7% from 60 patients [28] . Further, study Foo et al. (2014) confirmed variant in 1 of controls (0.25%) and none of patients [26] .
The third mutation was p.Ser633Phe. The variant changes polar amino acid for nonpolar in evolutionarily conserved region (phyloP score 4.2). It was found in 3/0p/c. Both the SIFT (score 0.002) and the PolyPhen-2 (score 0.971) evaluated the variant as a pathogenic.
Concerning the tau gene MAPT missense mutations p.Gly272Val, p.Asn279Lys, p.Pro301Leu, p.Pro301Ser, p.Arg406Trp, p.Gly389Arg, p.Val337Met and p.Ser305Asn were found in the patients with frontotemporal dementia type of Parkinsonism [29] [30] [31] [32] [33] [34] [35] [36] [37] . The substitution mutation (rs63750072; p.Gln230Arg) found in our study exchanges uncharged polar amino acids for alkaline in MAPT gene. The variant was evaluated by prediction tools as a pathogenic (SIFT score 0.003, PolyPhen-2 score 0.992) and the region is evolutionarily conserved (phyloP score 2.2). Jin et al., 2012 identified this variant in 10% patients and in 5.8% controls [38] . According to Deters et al. (2014) , the variant is in association with the level of tau protein expression in cerebrospinal fluid [39] .
Mutation p.Arg404Trp in HTRA2 gene can increase risk for Parkinsonism [40] . Mutation p.Gly399Ser that has been identified in sporadic form can contribute to the development of the disease probably due to disturbing of protease activity of the enzyme [41] . Omi/HtrA2 interacts in vitro with PINK1 and may undergo to phosphorylation which is PINK1 dependent and the substitution of phosphorylationable with non-phosphorylationable sites (p.Ser400Ala) reduces the protease activity [42] . Another mutation p.Ala141Ser which changes the protease activity was also described in patients with Parkinsonism [41] .
The variant (rs72470545; p.Gly399Ser) we described is located in evolutionarily conserved site (phyloP score 5.7) in HTRA2 gene and LOXL3 gene. [44] . Further, study Tzoulis et al. (2015) also did not confirm association between the variant and tremor [45] .
None of found variants has unambiguously pathogenic nature and has not yet been repeatedly described as pathogenic in literature.
Effect size for 40 samples (alpha=0.05) with 80% probability of variant clinical effect was calculated to be 0. 44. So to reach this value the frequency of mutation should be 6 times higher in patients compare to controls for MAF 0.01 [46] . Our results and comparisons ( 
